Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems

Journal of the National Cancer Institute

Volumn 96, Issue 5, 2004, Pages 353-356

  Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HAPTOGLOBIN; INTER ALPHA TRYPSIN INHIBITOR; PLASMA PROTEIN; PREALBUMIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; VITAMIN D BINDING PROTEIN; PROTEOME;

ANALYTIC METHOD; ARTIFACT; BIOINFORMATICS; BIOTECHNOLOGY; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; NOTE; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; ANIMAL; ARTICLE; BIOLOGY; EPIDEMIOLOGY; METABOLISM; METHODOLOGY; NEOPLASM;

ANIMALS; BIOTECHNOLOGY; COMPUTATIONAL BIOLOGY; CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DIAGNOSIS; HUMANS; NEOPLASMS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542378202     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh056     Document Type: Note

References (26)

1. Powell K. Proteomics delivers on promise of cancer biomarkers. Nat Med 2003;9:980.
2. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
3. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
4. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
5. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
6. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
7. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1:683-95.
8. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem 2001;47:1901-11.
9. Service RF. Genetics and medicine. Recruiting genes, proteins for a revolution in diagnostics. Science 2003;300:236-9.
10. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360:170.
11. Diamandis EP. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2003;95:489-90.
12. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-5.
13. Diamandis EP. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol. In press 2004.
14. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-6.
15. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. 2nd ed. Philadelphia (PA): Saunders; 1994.
16. Zhang Z, Bast RC Jr, Fung ET, Yu Y, Li J, Rosenzweig J, et al. A panel of three potential biomarkers discovered from serum proteomic profiling improves sensitivity of CA125 in the detection of early stage ovarian cancer-a multi-institutional study (abstract 5739). Proc AACR 2003.
17. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11.
18. Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, et al. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 2003;61:1261-5.
19. Mueller WK, Handschumacher R, Wade ME. Serum haptoglobin in patients with ovarian malignancies. Obstet Gynecol 1971;38:427-35.
20. Fish RG, Gill TS, Adams M, Kerby I. Serum haptoglobin and alpha 1-acid glycoprotein as indicators of the effectiveness of cis-diamminedichloroplatinum (CDDP) in ovarian cancer patients - a preliminary report. Eur J Cancer Clin Oncol 1984;20:625-30.
21. Fish RG, Gill TS, Adams M, Faqeera F, Kerby I. Changes in serum acute phase proteins in ovarian cancer patients receiving cis-diamminedichloruplatinum (CDDP) infusion therapy. Clin Biochem 1984;17:39-41.
22. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83.
23. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4:24. Available at: Http://www.biomedcentral.com/1471-2105/4/24. [Last accessed January 8, 2004.]
24. Petricoin E 3rd, Liotta LA. Counterpoint: The vision for a new diagnostic paradigm. Clin Chem 2003;49:1276-8.
25. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-72.
26. Walsh PC. Serum proteomic patterns for detection of prostate cancer. J Urol 2003;169:1592.